EMC China Lab

Evaluation of Chronic Toxicity and Carcinogenicity of Medical Devices

Views :
Update time : 2025-03-01

With the implementation of ISO 10993-1:2018, most devices that have prolonged contact with the human body (>30 days) now require an evaluation of chronic toxicity and carcinogenicity as part of their biological risk assessment. In Table A.1 (iso 10993-1:2018), these biological endpoints are marked with an "E", indicating that they must be evaluated during risk assessment. This evaluation can be conducted using existing data, additional endpoint-specific tests, or a justified rationale explaining why additional data are unnecessary. The inclusion of these biological evaluation endpoints has also drawn regulatory attention, with review feedback requiring further refinement of chronic toxicity and carcinogenicity assessments based on Table A.1.

 

Evaluation of Chronic Toxicity and Carcinogenicity of Medical Devices(图1)


Chronic Toxicity Test (Project Duration: ~8–14 months)

Chronic toxicity is a systemic toxicity study conducted by repeated or continuous exposure to the test sample throughout a significant portion of the animal's lifespan to observe any adverse effects. Animals should be continuously exposed for 6–12 months. When using rodents (rats, mice) for single-dose group studies, each group should include at least 30 animals (15 per sex). The evaluation of repeated exposure studies is based on body weight, clinical observations, hematology, clinical biochemistry, gross pathology, histopathology, and other test indicators.

 

Carcinogenicity Test (Project Duration: ~32–34 months)

The purpose of the carcinogenicity test is to assess tumor development in test animals during or after exposure to different doses of the test material through appropriate routes, covering major life stages of the animals.

 

- If an extract-based test is used, a standalone carcinogenicity study can be conducted according to OECD TG 451, or a combined chronic toxicity and carcinogenicity study can be conducted following OECD TG 453 to comprehensively evaluate both biological endpoints while considering the possibility of solid-state carcinogenicity.

- When evaluating the carcinogenicity of a medical device using a single animal species, the selection and justification should follow ISO 10993-2.

- For rodents, each group should include at least 50 animals per sex, with the study typically lasting 24 months to cover most of the animal’s lifespan.

 

Evaluation criteria include body weight, clinical observations, tumor formation and progression, hematology, gross pathology, histopathology, and other test indicators. Although transgenic animals can be used for carcinogenicity tests, their application in medical device evaluations has not yet been established.

 

Alternatives to Animal Testing for Chronic Toxicity and Carcinogenicity Evaluations

Both chronic toxicity and carcinogenicity studies involve long-term animal testing, posing significant financial and time challenges for product development. So, is animal testing always necessary for evaluating these biological endpoints?

 

According to iso 10993-18 (Material Chemical Characterization) and ISO 10993-17 (Toxicological Risk Assessment), toxicological evaluations based on material characterization can be used for assessing systemic toxicity endpoints, including:

 

- Systemic toxicity (acute, subacute, subchronic, and chronic toxicity)

- Genotoxicity

- Reproductive toxicity

- Carcinogenicity

 

Therefore, when determining whether to conduct chronic toxicity and carcinogenicity studies, it is essential to first consider the intended use and classification of the device to identify whether these biological endpoints require evaluation.

 

Manufacturers should leverage existing product information as much as possible, including raw materials, manufacturing processes, preclinical and clinical data (if available). When additional studies are necessary to support risk assessment, a tiered approach is recommended:

 

1. Prioritize chemical and physical characterization

2. Perform in vitro screening tests

3. Review characterization and in vitro test results before proceeding with animal testing

4. Justify the necessity of long-term animal studies

 

By following this approach, the biological risk assessment can be conducted in a scientifically rational and efficient manner.


Email:hello@jjrlab.com


Leave Your Message


Write your message here and send it to us


Related News
Read More >>
ROHS and Weee Compliance ROHS and Weee Compliance
05 .12.2026
RoHS and WEEE directives control hazardous substances and e-waste; JJR LAB offers third-party testin...
Waste of Electrical and Electronic Equipment Weee Waste of Electrical and Electronic Equipment Weee
05 .12.2026
WEEE EU EPR: producers register, fund recycling, label, report across member states. JJR LAB incl fe...
Low Voltage Directive CE Marking Low Voltage Directive CE Marking
05 .12.2026
LVD CE Marking covers EU safety for 50–1000VAC/75–1500VDC products. JJR LAB provides testing & c...
What are CE EMC Testing Requirements What are CE EMC Testing Requirements
05 .12.2026
CE EMC testing ensures EU compliance (EN 55032/55035/61000, RED). JJR LAB offers EMI/EMS, ESD, surge...
What are the CE EMC standards What are the CE EMC standards
05 .12.2026
CE EMC standards ensure EU devices meet emission and immunity rules. JJR LAB provides EN 55032/55035...
RF Testing Companies RF Testing Companies
05 .11.2026
RF Testing Companies EU third-party labs ensure wireless compliance via FCC/CE EMC EMI SAR OTA tests...
European WEEE Directive European WEEE Directive
05 .11.2026
EU WEEE 2012/19/EU: producers register, label, report, finance e-waste recycling (15 categories EPR)...
European Authorised Representative European Authorised Representative
05 .11.2026
EU Authorised Representative (EU AR) is EU compliance agent for non-EU medical devices under MDR/IVD...

Leave Your Message